These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 19170711

  • 1. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.
    Ranadive SA, Ersoy B, Favre H, Cheung CC, Rosenthal SM, Miller WL, Vaisse C.
    Clin Endocrinol (Oxf); 2009 Sep; 71(3):388-93. PubMed ID: 19170711
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
    Robben JH, Sze M, Knoers NV, Deen PM.
    Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
    [Abstract] [Full Text] [Related]

  • 4. Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation.
    Prosperi F, Suzumoto Y, Marzuillo P, Costanzo V, Jelen S, Iervolino A, Guarino S, La Manna A, Miraglia Del Giudice E, Perna AF, Zacchia M, Cordat E, Capasso G, Trepiccione F.
    Sci Rep; 2020 Oct 02; 10(1):16383. PubMed ID: 33009446
    [Abstract] [Full Text] [Related]

  • 5. Identification and characterization of a novel X-linked AVPR2 mutation causing partial nephrogenic diabetes insipidus: a case report and review of the literature.
    Neocleous V, Skordis N, Shammas C, Efstathiou E, Mastroyiannopoulos NP, Phylactou LA.
    Metabolism; 2012 Jul 02; 61(7):922-30. PubMed ID: 22386940
    [Abstract] [Full Text] [Related]

  • 6. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
    Cheong HI, Cho HY, Park HW, Ha IS, Choi Y.
    Nephrology (Carlton); 2007 Apr 02; 12(2):113-7. PubMed ID: 17371330
    [Abstract] [Full Text] [Related]

  • 7. A novel AVPR2 splice site mutation leads to partial X-linked nephrogenic diabetes insipidus in two brothers.
    Schernthaner-Reiter MH, Adams D, Trivellin G, Ramnitz MS, Raygada M, Golas G, Faucz FR, Nilsson O, Nella AA, Dileepan K, Lodish M, Lee P, Tifft C, Markello T, Gahl W, Stratakis CA.
    Eur J Pediatr; 2016 May 02; 175(5):727-33. PubMed ID: 26795631
    [Abstract] [Full Text] [Related]

  • 8. Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.
    Makita N, Sato T, Yajima-Shoji Y, Sato J, Manaka K, Eda-Hashimoto M, Ootaki M, Matsumoto N, Nangaku M, Iiri T.
    J Biol Chem; 2016 Oct 21; 291(43):22460-22471. PubMed ID: 27601473
    [Abstract] [Full Text] [Related]

  • 9. Functional characterization of vasopressin receptor 2 mutations causing partial and complete congenital nephrogenic diabetes insipidus in Thai families.
    Sahakitrungruang T, Tee MK, Rattanachartnarong N, Shotelersuk V, Suphapeetiporn K, Miller WL.
    Horm Res Paediatr; 2010 Oct 21; 73(5):349-54. PubMed ID: 20389105
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Functional characterization of a loss-of-function mutant I324M of arginine vasopressin receptor 2 in X-linked nephrogenic diabetes insipidus.
    Wang L, Guo W, Fang C, Feng W, Huang Y, Zhang X, Liu M, Cui J.
    Sci Rep; 2021 May 26; 11(1):11057. PubMed ID: 34040143
    [Abstract] [Full Text] [Related]

  • 12. Altered agonist sensitivity of a mutant v2 receptor suggests a novel therapeutic strategy for nephrogenic diabetes insipidus.
    Erdélyi LS, Balla A, Patócs A, Tóth M, Várnai P, Hunyady L.
    Mol Endocrinol; 2014 May 26; 28(5):634-43. PubMed ID: 24628417
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus.
    Li JH, Chou CL, Li B, Gavrilova O, Eisner C, Schnermann J, Anderson SA, Deng CX, Knepper MA, Wess J.
    J Clin Invest; 2009 Oct 26; 119(10):3115-26. PubMed ID: 19729836
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Vasopressin type 2 receptor V88M mutation: molecular basis of partial and complete nephrogenic diabetes insipidus.
    Bockenhauer D, Carpentier E, Rochdi D, van't Hoff W, Breton B, Bernier V, Bouvier M, Bichet DG.
    Nephron Physiol; 2010 Oct 26; 114(1):p1-10. PubMed ID: 19816050
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model.
    Robben JH, Knoers NV, Deen PM.
    Am J Physiol Renal Physiol; 2005 Aug 26; 289(2):F265-72. PubMed ID: 16006591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.